QIAGEN (QGEN)
(Real Time Quote from BATS)
$45.93 USD
+0.25 (0.55%)
Updated Sep 19, 2024 01:42 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
QGEN 45.93 +0.25(0.55%)
Will QGEN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for QGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for QGEN
QGEN Stock Likely to Gain From Newly Launched Assays for QIAcuity
QGEN Stock Likely to Gain From Innovation Amid Competition
QGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can QGEN Stock Gain From the Expanded Bio-Manguinhos/Fiocruz Alliance?
With HOLX Stock Near 52-Week High, Should You Buy More or Play Safe?
QIAGEN Stock Likely to Gain on Collaboration for APOE Genotyping
Other News for QGEN
QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform
Qiagen launches 100 new assays for its digital PCR to study cancer
IN BRIEF: Qiagen extends collaboration on blood screening in Brazil
QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil?s national screening programs
Qiagen and Bio-Manguinhos/Fiocruz collaborate to enhance malaria screening